Cassiopea selects DATATRAK platform for significant global study

Jul 15 2015NewsGuard 100/100 Score

DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified dClinical™ technologies and delivering related services for the clinical trials industry, today announced that Cassiopea S.p.A., the newly IPO'd former subsidiary of longtime partner Cosmo Pharmaceuticals SA has selected DATATRAK for a significant global study.

"Technology should support clinical research, not complicate it," said Laurence P. Birch, Chairman and CEO, DATATRAK. "As long time DATATRAK users, Cosmo Pharmaceuticals knows firsthand that we simplify clinical research. We look forward to supporting the vital research of Cassiopeia and delivering an exceptional customer experience," concluded Birch.

"Success in clinical research requires software that lets us focus on the trial. It must be easy to use, protect patients, and provide insight on demand. DATATRAK delivers technology that supports our work without adding complicated processes," said Louise Dube, Director of R&D of Cassiopea S.p.A.

SOURCE DATATRAK International, Inc.

Posted in: Device / Technology News | Medical Research News

Tags: , , , , , ,

Comments (0)

Suggested Reading

New research explores how antimicrobial exposure affects Parkinson’s disease risk
Research suggests no need for yellow fever vaccine booster after initial dose
Squid-inspired technology could replace needles for medications and vaccines
Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients
Can soda taxes fight obesity? New research adds to the debate
New research explores how omega-3 and omega-6 fatty acids may impact cancer rates
Antibiotic activity altered by interaction with nanoplastics, new research shows
BMI's influence on disease pathogenesis uncovered in new research

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Research reveals only a few brain regions remain untouched by transition to motherhood